As Beovu Debut Nears, Novartis Set to Push Longer Dosing Interval, Pivotal Data in Battle against Eylea
To read the full story
Related Article
- Novartis Launches AMD Drug Beovu in Japan
May 26, 2020
- Daiichi Sankyo’s Enhertu, Novartis’ Beovu, Novo’s Ozempic OK’ed for Listing on May 20
May 13, 2020
- Gene Techno CEO Eyes Lucentis Biosimilar Launch in November 2021, Expects Share of “At Least 30%”
April 23, 2020
- Bayer’s Eylea Effective at Both 12-Week and 16-Week Intervals: PIV Study
February 13, 2020
BUSINESS
- MSD’s Anti-MRSA Drug Cubicin Filed for Pediatric Use
January 28, 2021
- Chugai Drops Suit over Edirol Substance Patent, Row Continues for Method-of-Use
January 28, 2021
- BioAge Gets US/Europe Rights for Shionogi’s COVID-19 Treatment
January 27, 2021
- Pfizer’s Methotrexate 1000 mg Hit by Stock-Out on Flaws at German Manufacturing Site
January 27, 2021
- Kenei to Fight Maruho’s Claim over Healmild Trademark to the End
January 27, 2021
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…